Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease

Geriatrics and Gerontology International

Volumn 17, Issue 2, 2017, Pages 211-218

  Furukawa, Katsutoshi ^a   Tomita, Naoki ^a   Uematsu, Daisuke ^b   Okahara, Kazunori ^c   Shimada, Hiroyuki ^d   Ikeda, Masaki ^e   Matsui, Toshifumi ^f   Kozaki, Koichi ^g   Fujii, Masahiko ^h   Ogawa, Tatsuji ⁱ   Umegaki, Hiroyuki ^j   Urakami, Katsuya ^k   Nomura, Hiroshi ^l   Kobayashi, Naoto ^m   Nakanishi, Aki ⁿ   Washimi, Yukihiro ^o   Yonezawa, Hisashi ^p   Takahashi, Satoshi ^p   Kubota, Masaharu ^q   Wakutani, Yosuke ^r   Ito, Daisuke ^s   Sasaki, Takahiro ^t   Matsubara, Etsuro ^u,x   Une, Kaori ^a   Ishiki, Aiko ^a   Yahagi, Yukie ^v   Shoji, Mikio ^u   Sato, Hiroyasu ^v   Terayama, Yasuo ^p   Kuzuya, Masafumi ^j   Araki, Nobuo ^t   Kodama, Manabu ^w   Yamaguchi, Takuhiro ^v   Arai, Hiroyuki ^a   more..

^a TOHOKU UNIVERSITY   (Japan)

^b Uematsu Neurological Clinic   (Japan)

^c Keimei Memorial Hospital   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KURIHAMA NATIONAL HOSPITAL   (Japan)

^g KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Yamagata Kosei Hospital   (Japan)

ⁱ Aoba Neurosurgical Clinic   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k TOTTORI UNIVERSITY   (Japan)

^l Hiroshi Nomura Neurology Clinic   (Japan)

^m Azuma Street Clinic ^*  (Japan)

ⁿ Osaka City Kousaiin Hospital   (Japan)

^o NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^p IWATE MEDICAL UNIVERSITY   (Japan)

^q Kusakabe Memorial Hospital   (Japan)

^r Kurashiki Heisei Hospital   (Japan)

^s KEIO UNIVERSITY   (Japan)

^t SAITAMA MEDICAL UNIVERSITY   (Japan)

^u HIROSAKI UNIVERSITY   (Japan)

^v TOHOKU UNIVERSITY HOSPITAL   (Japan)

^w Kodama Hospital   (Japan)

^x OITA UNIVERSITY   (Japan)

more..

Author keywords

Alzheimer's disease; behavioral and psychological symptoms of dementia; Kampo medicine; Neuropsychiatric Inventory Brief Questionnaire Form; Yokukansan

Indexed keywords

HERBACEOUS AGENT; PLACEBO; UNCLASSIFIED DRUG; YOKUKANSAN;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BEHAVIOR; CLINICAL TRIAL; NEUROPSYCHOLOGICAL TEST; PHYTOTHERAPY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; PHYTOTHERAPY;

EID: 84952690888     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12696     Document Type: Article

References (26)

1. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; 8 (Suppl 3): 497–500.
2. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the cache county study on memory in aging. Am J Psychiatry 2000; 157: 708–714.
3. Ferri CP, Ames D, Prince M. Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr 2004; 16: 441–459.
4. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049–1051.
5. Coen RF, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 331–336.
6. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002; 17: 403–408.
7. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596–608.
8. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210–216.
9. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525–1538.
10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–1943.
11. Iwasaki K, Satoh-Nakagawa T, Maruyama M et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005; 66: 248–252.
12. Mizukami K, Asada T, Kinoshita T et al. A randomized cross-over study of a traditional Japanese medicine (kampo), Yokukansan, in the treatment of the behavioral and psychological symptoms of dementia. Int J Neuropsychopharmacol 2009; 12: 191–199.
13. Hayashi Y, Ishida Y, Inoue T et al. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 541–545.
14. Iwasaki K, Kosaka K, Mori H et al. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of Yokukansan, a traditional Japanese medicine. Psychogeriatrics 2012; 12: 235–241.
15. Nagata K, Yokoyama E, Yamazaki T et al. Effects of Yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial. Phytomedicine 2012; 19: 524–528.
16. Okahara K, Ishida Y, Hayashi Y et al. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 532–536.
17. Monji A, Takita M, Samejima T et al. Effect of Yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 308–311.
18. Matsuda Y, Kishi T, Shibayama H, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2013; 28: 80–86.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939–944.
20. Kaufer DI, Cummings JL, Ketchel P et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233–239.
21. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
22. Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioral and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008; 23: 393–400.
23. Streim JE, Porsteinsson AP, Breder CD et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16: 537–550.
24. Terawaki K, Ikarashi Y, Sekiguchi K, Nakai Y, Kase Y. Partial agonistic effect of Yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol 2010; 127: 306–312.
25. Egashira N, Iwasaki K, Ishibashi A et al. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT) 2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1516–1520.
26. Kawakami Z, Ikarashi Y, Kase Y. Glycyrrhizin and its metabolite 18β-glycyrrheetinic acid in glycyrrhiza, a constituent herb of Yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol 2010; 626: 154–158.